Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JNJ-79635322 |
Synonyms | |
Therapy Description |
JNJ-79635322 is a trispecific antibody that targets TNFRSF17 (BCMA) and GPRC5D on tumor cells, and CD3 on T-cells, which potentially induces cytotoxicity against tumor cells (Blood (2023) 142 (Supplement 1): 456). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JNJ-79635322 | JNJ 79635322|JNJ79635322 | CD3 Antibody 99 TNFRSF17 Antibody 20 | JNJ-79635322 is a trispecific antibody that targets TNFRSF17 (BCMA) and GPRC5D on tumor cells, and CD3 on T-cells, which potentially induces cytotoxicity against tumor cells (Blood (2023) 142 (Supplement 1): 456). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05652335 | Phase I | JNJ-79635322 | A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | NLD | GBR | FRA | ESP | BEL | 1 |